‘Can’t launch vaccine till…’: Serum MD talks of issues between FDA and Novavax | Latest News India - Hindustan Times
close_game
close_game

‘Can’t launch vaccine till…’: Serum MD talks of issues between FDA and Novavax

By, New Delhi
Aug 13, 2021 04:16 PM IST

Cyrus Poonawalla is hopeful that the issues will be resolved by October-end so that the vaccine, Covovax, can be launched in India.

In another indication that the launch in India of the second batch of Novavax’s vaccine candidate against the coronavirus disease (Covid-19) could get delayed, Serum Institute of India (SII) chairperson Cyrus Poonawalla said on Friday that there are issues between the US Food and Drug Administration (USFDA) and Novavax. These issues, Poonawalla said, are likely to be cleared by October-end.

Vials labelled "COVID-19 Coronavirus Vaccine" and sryinge are seen in front of displayed Novavax logo in this illustration (Reuters).
Vials labelled "COVID-19 Coronavirus Vaccine" and sryinge are seen in front of displayed Novavax logo in this illustration (Reuters).

“We can’t launch Novavax’s vaccine unless we get a license to launch it. The parent American company has some issues with the USFDA, which should be cleared by the end of October. We will get the license only when the company gets one from the FDA. We are trying to obtain the license ahead of the parent company, but it’s an uphill task,” the Serum chairman and MD said, according to news agency ANI. 

Hindustan Times - your fastest source for breaking news! Read now.

 

Poonawalla’s remarks are on the lines of those made by his son, Serum CEO Adar Poonwalla, who said last Friday that the company hopes to manufacture the vaccine, Covovax, for adults by October and by early 2022 for children.

Also Read | 'Hope to launch Covovax for adults in October, in early 2022 for kids': Adar Poonwalla

Pune-based SII, the world’s largest vaccine manufacturer, has partnered with the American pharmaceutical firm to manufacture the latter’s coronavirus vaccine in India. SII manufactured the first batch of Covovax vaccines in June. The second batch, meanwhile, was expected to be manufactured in September.

Also Read | SII to introduce Novavax vaccine in India by September: Report

Novavax has developed Covovax in partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). The company said that its protein-based vaccine offered 100% protection against moderate and severe Covid-19, with an overall efficacy of 100%.

Thus far, five coronavirus vaccines have been approved in India, of which two --Covaxin and Covishield-- were the first to be cleared, and are the two most prominently used shots. Covishield, just like Covovax, is manufactured by the SII and is the local name of the shot developed by Oxford University and AstraZeneca Inc. India’s vaccination drive began on January 16 and a total of 529,582,956 doses have been administered till now, including 5,731,574 in the last 24 hours, according to the Union ministry of health and family welfare (MoHFW) dashboard.

 

Unveiling Elections 2024: The Big Picture', a fresh segment in HT's talk show 'The Interview with Kumkum Chadha', where leaders across the political spectrum discuss the upcoming general elections. Watch now!

Get Current Updates on India News, Election 2024, Arvind Kejriwal News Live, Bihar Board 10th Result 2024 Live along with Latest News and Top Headlines from India and around the world.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, March 28, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On